Cleveland Clinic Cancer Center experts present data at 2018 ASCO Annual Meeting

Source: Eurek Alert, June 2018

At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, researchers from Cleveland Clinic Cancer Center will present data from several new studies, including a prospective clinical trial examining non-small cell lung cancer cells’ response to immunotherapy; research on germline testing for melanoma; and interim results from a study testing a vaccine for glioblastoma.

“Clinical research is critical to the development of treatment options we can offer patients that extend their lives and improve their quality of life," said Brian Bolwell, M.D., FACP, chairman of Cleveland Clinic Taussig Cancer Institute. “Clinical trials, involving immunotherapy and genomics in particular, are a priority for our cancer center and the research we are presenting at ASCO is a testament to that."

• Abstract 12001 title: Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results; Dr. Vamsidhar Velcheti, oral presenter; Tuesday, June 5